Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 49 articles: HTML format

Single Articles

February 2024
1. WANG S, Dai H
   Crazy-Paving Pattern in Pulmonary Sarcoidosis.
   N Engl J Med. 2024;390:e21.
   PubMed    
   
   
   
2. WOOD RA, Togias A, Sicherer SH, Shreffler WG, et al
   Omalizumab for the Treatment of Multiple Food Allergies.
   N Engl J Med. 2024 Feb 25. doi: 10.1056/NEJMoa2312382.
   PubMed     Abstract available
   
   
   
3. WONG GWK
   Options for Multiple Food Allergies - Food Avoidance or Pharmacologic Treatment?
   N Engl J Med. 2024 Feb 25. doi: 10.1056/NEJMe2400807.
   PubMed    
   
   
   
4. LONGHURST HJ, Lindsay K, Petersen RS, Fijen LM, et al
   CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
   N Engl J Med. 2024;390:432-441.
   PubMed     Abstract available
   
   
   November 2023
5. MOSNAIM G
   Asthma in Adults. Reply.
   N Engl J Med. 2023;389:10.
   PubMed    
   
   
   
6. BELL KJL, Kazda L, Parker G
   Asthma in Adults.
   N Engl J Med. 2023;389:10.
   PubMed    
   
   
   
7. RABIN AS, Junck L, Shankar HM
   Asthma in Adults.
   N Engl J Med. 2023;389:10.
   PubMed    
   
   
   
8. SELINGER S
   Asthma in Adults.
   N Engl J Med. 2023;389:10.
   PubMed    
   
   
   
9. WONG JCY, Li PH
   Large-Bowel Obstruction from Hereditary Angioedema.
   N Engl J Med. 2023;389:e41.
   PubMed    
   
   
   October 2023
10. KWATRA SG, Yosipovitch G, Legat FJ, Reich A, et al
    Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    N Engl J Med. 2023;389:1579-1589.
    PubMed     Abstract available
    
    
    
11. JANUSONYTE E, Punchera J
    Shiitake Dermatitis.
    N Engl J Med. 2023;389:1415.
    PubMed    
    
    
    September 2023
12. MOSNAIM G
    Asthma in Adults.
    N Engl J Med. 2023;389:1023-1031.
    PubMed    
    
    
    July 2023
13. AGUSTI A
    Biologics for COPD - Finally Here.
    N Engl J Med. 2023;389:274-275.
    PubMed    
    
    
    
14. WOLKOW N, Romo LV, Edwards CV, Stagner AM, et al
    Case 21-2023: A 61-Year-Old Man with Eyelid Swelling.
    N Engl J Med. 2023;389:166-175.
    PubMed    
    
    
    June 2023
15. SILVERBERG JI, Guttman-Yassky E, Gontijo Lima R
    Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply.
    N Engl J Med. 2023;388:2299-2300.
    PubMed    
    
    
    
16. SMITH B, Engel P, Wu JJ
    Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
    N Engl J Med. 2023;388:2299.
    PubMed    
    
    
    May 2023
17. TOGIAS A
    Good News for Toddlers with Peanut Allergy.
    N Engl J Med. 2023;388:1814-1815.
    PubMed    
    
    
    
18. GREENHAWT M, Sindher SB, Wang J, O'Sullivan M, et al
    Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
    N Engl J Med. 2023;388:1755-1766.
    PubMed     Abstract available
    
    
    April 2023
19. CONNOLLY CM, Christopher-Stine L
    Periorbital Edema in Dermatomyositis.
    N Engl J Med. 2023;388:e52.
    PubMed    
    
    
    March 2023
20. SILVERBERG JI, Guttman-Yassky E, Thaci D, Irvine AD, et al
    Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
    N Engl J Med. 2023 Mar 15. doi: 10.1056/NEJMoa2206714.
    PubMed     Abstract available
    
    
    
21. DELLON ES, Rothenberg ME, Bredenoord AJ
    Dupilumab in Patients with Eosinophilic Esophagitis. Reply.
    N Engl J Med. 2023;388:956-957.
    PubMed    
    
    
    
22. GREUTER T, Schoepfer AM
    Dupilumab in Patients with Eosinophilic Esophagitis.
    N Engl J Med. 2023;388:955-956.
    PubMed    
    
    
    January 2023
23. KAKURAI M, Oya K
    Atopic Eruption of Pregnancy.
    N Engl J Med. 2023;388:357.
    PubMed    
    
    
    December 2022
24. STRAUMANN A
    Biologics in Eosinophilic Esophagitis - Ready for Prime Time?
    N Engl J Med. 2022;387:2379-2380.
    PubMed    
    
    
    
25. DELLON ES, Rothenberg ME, Collins MH, Hirano I, et al
    Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
    N Engl J Med. 2022;387:2317-2330.
    PubMed     Abstract available
    
    
    
26. LANG DM
    Chronic Urticaria. Reply.
    N Engl J Med. 2022;387:2103.
    PubMed    
    
    
    
27. ROLLA G
    Chronic Urticaria.
    N Engl J Med. 2022;387:2102-2103.
    PubMed    
    
    
    
28. WEINBERGER M
    Chronic Urticaria.
    N Engl J Med. 2022;387:2102.
    PubMed    
    
    
    
29. BONNIN AJ
    Chronic Urticaria.
    N Engl J Med. 2022;387:2101-2102.
    PubMed    
    
    
    
30. DESCAMPS V
    Chronic Urticaria.
    N Engl J Med. 2022;387:2101.
    PubMed    
    
    
    September 2022
31. LANG DM
    Chronic Urticaria.
    N Engl J Med. 2022;387:824-831.
    PubMed    
    
    
    August 2022
32. PAPI A, Chipps BE, Cappelletti C
    Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. Reply.
    N Engl J Med. 2022;387:663.
    PubMed    
    
    
    
33. LIPWORTH BJ, Chan R, Stewart KE
    Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
    N Engl J Med. 2022;387:662-663.
    PubMed    
    
    
    July 2022
34. HUNG WK, Chung WH
    Drug Reaction with Eosinophilia and Systemic Symptoms.
    N Engl J Med. 2022;387:167.
    PubMed    
    
    
    June 2022
35. SCHATZ M
    Another Rescue Therapy Option for Patients with Moderate-to-Severe Asthma.
    N Engl J Med. 2022;386:2139-2140.
    PubMed    
    
    
    May 2022
36. PAPI A, Chipps BE, Beasley R, Panettieri RA Jr, et al
    Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
    N Engl J Med. 2022 May 15. doi: 10.1056/NEJMoa2203163.
    PubMed     Abstract available
    
    
    April 2022
37. BRYANT-STEPHENS T
    Breaking the Skin Color Barriers for Asthma Medications - It's Not Black, Brown, or White.
    N Engl J Med. 2022;386:1574-1575.
    PubMed    
    
    
    March 2022
38. LONGHURST HJ, Ameratunga R
    An Antisense Oligonucleotide for Hereditary Angioedema.
    N Engl J Med. 2022;386:1083-1085.
    PubMed    
    
    
    
39. BANERJI A, Phadke NA, Gottumukkala R, Sharma R, et al
    Case 8-2022: A 54-Year-Old Woman with Episodes of Swelling.
    N Engl J Med. 2022;386:1071-1079.
    PubMed    
    
    
    
40. FIJEN LM, Riedl MA, Bordone L, Bernstein JA, et al
    Inhibition of Prekallikrein for Hereditary Angioedema.
    N Engl J Med. 2022;386:1026-1033.
    PubMed     Abstract available
    
    
    February 2022
41. ISRAEL E, Cardet JC, Carroll JK, Fuhlbrigge AL, et al
    Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma.
    N Engl J Med. 2022 Feb 26. doi: 10.1056/NEJMoa2118813.
    PubMed     Abstract available
    
    
    January 2022
42. BRUSSELLE GG, Koppelman GH
    Biologic Therapies for Severe Asthma.
    N Engl J Med. 2022;386:157-171.
    PubMed    
    
    
    December 2021
43. GONZALEZ BURCHARD E, Borrell LN
    Need for Racial and Ethnic Diversity in Asthma Precision Medicine.
    N Engl J Med. 2021;385:2297-2298.
    PubMed    
    
    
    
44. BACHARIER LB, Maspero JF, Katelaris CH, Fiocchi AG, et al
    Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
    N Engl J Med. 2021;385:2230-2240.
    PubMed     Abstract available
    
    
    
45. ZHANG B, Ma L
    Transverse Nasal Creases.
    N Engl J Med. 2021;385:2281.
    PubMed    
    
    
    October 2021
46. BARDIN PG, Foster PS
    Clinical Translation of Basic Science in Asthma.
    N Engl J Med. 2021;385:1714-1717.
    PubMed    
    
    
    
47. ASKENASE PW
    Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses.
    N Engl J Med. 2021;385:1720-1721.
    PubMed    
    
    
    
48. BRIGHTLING CE, Nair P, Cousins DJ, Louis R, et al
    Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.
    N Engl J Med. 2021;385:1669-1679.
    PubMed     Abstract available
    
    
    
49. WECHSLER ME, Ruddy MK, Pavord ID, Israel E, et al
    Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
    N Engl J Med. 2021;385:1656-1668.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.